SMTI · XBRL financial data

Sanara MedTech financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SMTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	15,587	—	—	—	—	—
Revenue from contracts with customers	15,587	24,144	45,843	64,990	86,672	103,118
Cost of revenue	1,617	2,311	6,361	7,853	8,140	7,521
Gross profit	13,970	21,833	39,482	57,137	78,533	95,597
Research and development	40	559	3,367	4,132	5,703	5,072
Selling, general and administrative	—	28,053	45,976	56,995	76,560	78,717
General and administrative	18,684	28,053	—	—	15,386	16,706
Total operating expenses	19,005	29,209	51,714	61,352	85,248	88,292
Operating income (loss)	(5,035)	(7,376)	(12,232)	(4,215)	(6,715)	7,305
Interest expense	12	1	285	476	3,128	6,760
Other income (expense)	589	(618)	(1,705)	(225)	(3,196)	(7,698)
Income tax expense (benefit)	0	—	(5,845)	—	(48)	—
Net income (loss)	(4,356)	(7,994)	(7,937)	(4,303)	(9,665)	(37,563)
Earnings per share, basic USD per share	(0.76)	(1.08)	(1.00)	(0.52)	(1.14)	(4.36)
Earnings per share, diluted USD per share	(0.76)	—	(1.00)	(0.52)	(1.14)	(4.36)
Weighted average shares, basic thousands of shares	5,735	7,342	7,907	8,279	8,484	8,623
Weighted average shares, diluted thousands of shares	5,735	7,342	7,907	8,279	8,484	8,623

Fiscal years (SMTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	455	18,653	8,959	5,147	15,878	16,579
Accounts receivable	0	80	6,806	—	—	11,998
Inventory	1,148	2,048	3,549	4,718	2,753	3,949
Prepaid and other current assets	612	917	1,105	608	1,124	949
Total current assets	4,482	24,608	20,617	19,006	33,306	33,542
Property and equipment, net	679	1,630	1,416	1,258	432	457
Right-of-use asset	468	413	806	1,995	1,448	2,076
Goodwill	—	—	3,602	3,602	3,602	3,602
Total assets	9,826	36,396	61,035	73,871	88,092	72,944
Accounts payable	271	438	1,393	—	—	2,339
Current portion of long-term debt	—	—	—	580	—	—
Total current liabilities	3,540	6,022	12,806	13,768	15,290	18,627
Long-term debt	—	—	—	9,113	30,689	45,971
Lease liability, non-current	356	222	505	1,737	1,237	1,869
Total liabilities	3,986	6,244	19,315	29,283	49,180	67,014
Accumulated deficit	(7,032)	(15,235)	(23,395)	(28,037)	(37,784)	(75,303)
Total stockholders' equity	6,151	30,640	41,828	44,832	39,404	5,938
Total liabilities and equity	9,826	36,396	61,035	73,871	88,092	72,944
Common shares outstanding (cover page) thousands of shares	7,617	7,814	8,377	8,623	8,902	9,167

Fiscal years (SMTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(4,356)	(7,994)	(7,937)	(4,303)	(9,665)	(37,563)
Stock-based compensation	1,403	2,669	2,703	3,443	4,436	5,155
Depreciation and amortization	291	—	—	—	4,923	3,946
Net cash from operating activities	(4,035)	(4,815)	(5,555)	(3,246)	(24)	6,787
Purchases of property and equipment	544	172	147	265	206	4,626
Net cash from investing activities	(2,744)	(5,285)	(3,512)	(10,207)	(6,612)	(14,974)
Proceeds from long-term debt	583	—	—	—	—	—
Net cash from financing activities	622	28,297	(627)	9,641	17,367	8,888
Net change in cash	(6,157)	18,197	(9,694)	(3,812)	10,731	701

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sight Sciences	79,753	23,388	(5,663)*	55.1M	14.1 quarters	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.